Literature DB >> 25445845

Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Aman P Singh1, Wojciech Krzyzanski, Steven W Martin, Gregory Weber, Alison Betts, Alaa Ahmad, Anson Abraham, Anup Zutshi, John Lin, Pratap Singh.   

Abstract

Prediction of human pharmacokinetics (PK) can be challenging for monoclonal antibodies (mAbs) exhibiting target-mediated drug disposition (TMDD). In this study, we performed a quantitative analysis of a diverse set of six mAbs exhibiting TMDD to explore translational rules that can be utilized to predict human PK. A TMDD model with rapid-binding approximation was utilized to fit PK and PD (i.e., free and/or total target levels) data, and average absolute fold error (AAFE) was calculated for each model parameter. Based on the comparative analysis, translational rules were developed and applied to a test antibody not included in the original analysis. AAFE of less than two-fold was observed between monkey and human for baseline target levels (R 0), body-weight (BW) normalized central elimination rate (K el/BW(-0.25)) and central volume (V c/BW(1.0)). AAFE of less than three-fold was estimated for the binding affinity constant (K D). The other four parameters, i.e., complex turnover rate (K int), target turnover rate (K deg), central to peripheral distribution rate constant (K pt) and peripheral to central rate constant (K tp) were poorly correlated between monkey and human. The projected human PK of test antibody based on the translation rules was in good agreement with the observed nonlinear PK. In conclusion, we recommend a TMDD model-based prediction approach that integrates in vitro human biomeasures and in vivo preclinical data using translation rules developed in this study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25445845      PMCID: PMC4365083          DOI: 10.1208/s12248-014-9690-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  32 in total

1.  Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method.

Authors:  Masataka Oitate; Shintaro Nakayama; Takashi Ito; Atsushi Kurihara; Noriko Okudaira; Takashi Izumi
Journal:  Drug Metab Pharmacokinet       Date:  2011-12-06       Impact factor: 3.614

2.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

3.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

4.  Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Authors:  Chee M Ng; Eric Stefanich; Banmeet S Anand; Paul J Fielder; Louis Vaickus
Journal:  Pharm Res       Date:  2006-11-30       Impact factor: 4.200

5.  Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.

Authors:  Y Zheng; H Scheerens; J C Davis; R Deng; S K Fischer; C Woods; P J Fielder; E G Stefanich
Journal:  Clin Pharmacol Ther       Date:  2010-12-29       Impact factor: 6.875

6.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

Authors:  Rong Deng; Suhasini Iyer; Frank-Peter Theil; Deborah L Mortensen; Paul J Fielder; Saileta Prabhu
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

7.  A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.

Authors:  Kenneth T Luu; Simon Bergqvist; Enhong Chen; Dana Hu-Lowe; Eugenia Kraynov
Journal:  J Pharmacol Exp Ther       Date:  2012-03-13       Impact factor: 4.030

Review 8.  Elimination mechanisms of therapeutic monoclonal antibodies.

Authors:  Mohammad A Tabrizi; Chih-Ming L Tseng; Lorin K Roskos
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

9.  MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.

Authors:  Heleen Scheerens; Zheng Su; Bryan Irving; Michael J Townsend; Yanan Zheng; Eric Stefanich; Vishala Chindalore; Clifton O Bingham; John C Davis
Journal:  Arthritis Res Ther       Date:  2011-10-26       Impact factor: 5.156

10.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Eugene O Major; Caroline Ryschkewitsch; Gary Fahle; Steven Fischer; Jean Hou; Blanche Curfman; Katherine Miszkiel; Nicole Mueller-Lenke; Esther Sanchez; Frederik Barkhof; Ernst-Wilhelm Radue; Hans R Jäger; David B Clifford
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

View more
  19 in total

1.  Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.

Authors:  Abhinav Tiwari; Anson K Abraham; John M Harrold; Anup Zutshi; Pratap Singh
Journal:  AAPS J       Date:  2016-12-21       Impact factor: 4.009

2.  Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect.

Authors:  Aman P Singh; Gail M Seigel; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Hsuan-Ping Cheng; Dhaval K Shah
Journal:  J Pharmacol Exp Ther       Date:  2020-04-09       Impact factor: 4.030

3.  Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).

Authors:  Aman P Singh; Dhaval K Shah
Journal:  AAPS J       Date:  2017-04-03       Impact factor: 4.009

4.  Measurement of Free Versus Total Therapeutic Monoclonal Antibody in Pharmacokinetic Assessment is Modulated by Affinity, Incubation Time, and Bioanalytical Platform.

Authors:  Jeffrey J Talbot; Dominador Calamba; Melody Pai; Mark Ma; Theingi M Thway
Journal:  AAPS J       Date:  2015-08-12       Impact factor: 4.009

5.  A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.

Authors:  Konstantinos Biliouris; Ivan Nestorov; Himanshu Naik; David Dai; Guangqing Xiao; Qin Wang; Alex Pellerin; Dania Rabah; Lawrence J Lesko; Mirjam N Trame
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

6.  FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.

Authors:  Mitchell C Brenner; Wojciech Krzyzanski; James Z Chou; Pierre E Signore; Cyra K Fung; David Guzman; Dongxia Li; Weihua Zhang; David R Olsen; Viet-Tam L Nguyen; Carolyn W Koo; Mark D Sternlicht; Kenneth E Lipson
Journal:  Pharm Res       Date:  2016-04-08       Impact factor: 4.200

7.  Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.

Authors:  P Singh; H Rong; T Gordi; J Bosley; I Bhattacharya
Journal:  Clin Transl Sci       Date:  2016-10-04       Impact factor: 4.689

8.  AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

Authors:  A M Stein; R Ramakrishna
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-04-04

9.  Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

Authors:  Aurelia H M de Vries Schultink; Robert P Doornbos; Alexander B H Bakker; Kees Bol; Mark Throsby; Cecile Geuijen; David Maussang; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Invest New Drugs       Date:  2018-05-05       Impact factor: 3.850

10.  A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.

Authors:  Tae Kyu Chung; Hyun A Lee; Sang-In Park; Do-Youn Oh; Keun-Wook Lee; Jin Won Kim; Jee Hyun Kim; Ahmi Woo; Su Jin Lee; Yung-Jue Bang; Howard Lee
Journal:  Clin Transl Sci       Date:  2021-01-25       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.